Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA ...

PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with ...

Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a chronic autoimmune condition that affects the protective layer around your nerves, usually starts with one of three options.

Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment aims to slow immune-driven demyelination and reduce inflammation. This can help protect nerve signaling and function. First-line CIDP ...

Myelin is the protective coating around nerves that helps electrical messages travel properly. When it is damaged, movement, vision, and fatigue can worsen. Demyelinating disease can affect the ...

The peripheral nervous system is the part of the nervous system outside the brain and spinal cord. It consists of nerves that carry information between the central nervous system and the extremities ...

Guillain-Barré Syndrome (GBS) is a rare autoimmune disease that affects the nervous system, causing muscle weakness, paralysis, and lack of sensitivity. In addition to drug treatment, physical therapy ...

Background To evaluate the efficacy of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients not responding to conventional immune therapies. Methods An open-label, ...